.png)
This journal has adopted the following models:
- Creative Commons Attribution License (CC-BY 2.0 UK)
- Publication Integrity and Ethics (P.I.E.) Guidelines
- Ethical Rules of Disclosure of the Association for Medical Ethics (AME)
- ICMJE Recommendations of the International Committee of Medical Journal Editors (ICMJE)
- Editorial Policy Statements of the Council of Science Editors (CSE)
Tracked/indexed by:
Google Scholar, JournalTOCs, EZB Nutzeranfragen, RoMEO, CrossRef, CNKI, J-Gate
OAPL (UK) archiving provider: British Library
Our publisher has negotiated a discount for its editors, reviewers and authors to undertake (distant learning- fully online) short courses related to research integrity and publication ethics, law and medical ethics, research governance, good ethical practice, leadership and management. These courses are approved by the Publication Integrity & Ethics.
A UK-based not-for-profit organization promoting integrity and ethics in the publishing sector through its guidelines and code of conduct.
P.I.E.'s main aim is to pave the way for a better publishing ethical environment that sets out the standards of a good and ethical editorial behaviour.
Whilst P.I.E. (π) promotes editorial freedom, at the same time, it also ensures that this freedom is not violated by editorial misconduct and plagiarism.
OAPL authors may choose to include the
OAPL standard ethics statements
in their submitted articles. It is assumed that all submitted original research studies, research studies, hypothesis, methodologies, short communications, case studies, case reports & case series have been conducted to the highest ethical standards.
Mishra M, Sachan S, Gupta S, Nigam RS, Gupta SP. QSTR with topological indices: Modeling of the acute toxicity of phenylsulfonyl carboxylates to vibrio fischeri using multiple regression analysis. OA Drug Design & Delivery 2014 Feb 25;2(1):3.
Level IIa
Caban S, Aytekin E, Sahin A, Capan Y. Nanosystems for drug delivery. OA Drug Design & Delivery 2014 Jan 18;2(1):2.
High Impact
Izat N, Yerlikaya F, Capan Y. A glance on the history of pharmaceutical quality by design. OA Drug Design & Delivery 2014 Jan 18;2(1):1.
High Impact
Wadood A, Ahmed N, Shah L, Ahmad A, Hassan H, Shams S. In-silico drug design: An approach which revolutionarised the drug discovery process. OA Drug Design & Delivery 2013 Sep 01;1(1):3.
High Impact
Esposito E, Drechsler M, Cortesi R. Microscopy characterisation of micro- and nanosystems for pharmaceutical use. OA Drug Design & Delivery 2013 Aug 01;1(1):2.
High Impact
Siddalingappa B, Nekkanti V, Betageri GV. Insoluble drug delivery technologies: Review of health benefits and business potentials. OA Drug Design & Delivery 2013 Aug 01;1(1):1.
High Impact
Wadood A, Ahmed N, Shah L, Ahmad A, Hassan H, Shams S. In-silico drug design: An approach which revolutionarised the drug discovery process. OA Drug Design & Delivery 2013 Sep 01;1(1):3.
High Impact
Siddalingappa B, Nekkanti V, Betageri GV. Insoluble drug delivery technologies: Review of health benefits and business potentials. OA Drug Design & Delivery 2013 Aug 01;1(1):1.
High Impact
Caban S, Aytekin E, Sahin A, Capan Y. Nanosystems for drug delivery. OA Drug Design & Delivery 2014 Jan 18;2(1):2.
High Impact
Izat N, Yerlikaya F, Capan Y. A glance on the history of pharmaceutical quality by design. OA Drug Design & Delivery 2014 Jan 18;2(1):1.
High Impact
Esposito E, Drechsler M, Cortesi R. Microscopy characterisation of micro- and nanosystems for pharmaceutical use. OA Drug Design & Delivery 2013 Aug 01;1(1):2.
High Impact
Mishra M, Sachan S, Gupta S, Nigam RS, Gupta SP. QSTR with topological indices: Modeling of the acute toxicity of phenylsulfonyl carboxylates to vibrio fischeri using multiple regression analysis. OA Drug Design & Delivery 2014 Feb 25;2(1):3.
Level IIa
Mishra M, Sachan S, Gupta S, Nigam RS, Gupta SP. QSTR with topological indices: Modeling of the acute toxicity of phenylsulfonyl carboxylates to vibrio fischeri using multiple regression analysis. OA Drug Design & Delivery 2014 Feb 25;2(1):3.
Level IIa
Caban S, Aytekin E, Sahin A, Capan Y. Nanosystems for drug delivery. OA Drug Design & Delivery 2014 Jan 18;2(1):2.
High Impact
Izat N, Yerlikaya F, Capan Y. A glance on the history of pharmaceutical quality by design. OA Drug Design & Delivery 2014 Jan 18;2(1):1.
High Impact
Wadood A, Ahmed N, Shah L, Ahmad A, Hassan H, Shams S. In-silico drug design: An approach which revolutionarised the drug discovery process. OA Drug Design & Delivery 2013 Sep 01;1(1):3.
High Impact
Esposito E, Drechsler M, Cortesi R. Microscopy characterisation of micro- and nanosystems for pharmaceutical use. OA Drug Design & Delivery 2013 Aug 01;1(1):2.
High Impact
Siddalingappa B, Nekkanti V, Betageri GV. Insoluble drug delivery technologies: Review of health benefits and business potentials. OA Drug Design & Delivery 2013 Aug 01;1(1):1.
High Impact
